Triple-Drug attack shows promise against rare blood cancer

NCT ID NCT05672173

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Dec 17, 2025 · Last updated May 16, 2026 · Updated 17 times

Summary

This study tests a combination of three drugs—lisocabtagene maraleucel (a personalized cell therapy), nivolumab (an immunotherapy), and ibrutinib (a targeted pill)—in 20 adults with Richter's transformation, an aggressive form of leukemia. The goal is to see if this triple therapy can shrink or eliminate cancer cells. Participants must have a confirmed diagnosis and agree to a tumor biopsy before treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA RICHTER SYNDROME